Dupont Capital Management Corp Trims Position in Abbott Laboratories (NYSE:ABT)

Dupont Capital Management Corp trimmed its holdings in Abbott Laboratories (NYSE:ABTFree Report) by 2.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 123,835 shares of the healthcare product maker’s stock after selling 3,221 shares during the period. Abbott Laboratories accounts for approximately 1.2% of Dupont Capital Management Corp’s portfolio, making the stock its 21st largest position. Dupont Capital Management Corp’s holdings in Abbott Laboratories were worth $13,631,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp raised its holdings in Abbott Laboratories by 1.9% during the second quarter. State Street Corp now owns 74,817,109 shares of the healthcare product maker’s stock worth $8,156,561,000 after purchasing an additional 1,362,889 shares in the last quarter. Morgan Stanley raised its holdings in Abbott Laboratories by 14.3% during the fourth quarter. Morgan Stanley now owns 38,966,499 shares of the healthcare product maker’s stock worth $4,278,132,000 after purchasing an additional 4,886,954 shares in the last quarter. Wellington Management Group LLP raised its holdings in Abbott Laboratories by 4.3% during the third quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock worth $3,022,564,000 after purchasing an additional 1,298,219 shares in the last quarter. Moneta Group Investment Advisors LLC raised its holdings in Abbott Laboratories by 104,649.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 30,247,436 shares of the healthcare product maker’s stock worth $3,320,866,000 after purchasing an additional 30,218,560 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Abbott Laboratories by 1.5% during the third quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock worth $2,229,122,000 after purchasing an additional 343,559 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $14,895,094.50. The disclosure for this sale can be found here. Insiders have sold a total of 56,435 shares of company stock valued at $6,451,298 over the last quarter. Company insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Down 0.1 %

Shares of NYSE ABT opened at $112.02 on Wednesday. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The firm’s 50 day moving average price is $115.06 and its 200 day moving average price is $106.67. The firm has a market cap of $194.37 billion, a P/E ratio of 34.36, a price-to-earnings-growth ratio of 2.74 and a beta of 0.74. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last announced its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.19. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The firm had revenue of $10.24 billion for the quarter, compared to analyst estimates of $10.19 billion. During the same quarter last year, the business earned $1.03 earnings per share. Abbott Laboratories’s revenue was up 1.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a yield of 1.96%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.48%.

Analyst Ratings Changes

Several research firms recently issued reports on ABT. Wells Fargo & Company increased their price target on shares of Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Royal Bank of Canada restated an “outperform” rating and set a $128.00 target price on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Raymond James upped their target price on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Finally, Barclays upped their target price on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $121.77.

Read Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.